Skip to main content

FTC sues to block Amgen’s acquisition of Horizon Therapeutics

Deal could allow Amgen to "entrench the monopoly positions" of two Horizon medications, regulators say.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.